Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Quest take ups Epigenomics' prostate cancer marker

This article was originally published in Clinica

Executive Summary

German cancer molecular diagnostics company Epigenomics has licensed its proprietary prostate cancer biomarker, mGSTP1, to US diagnostic testing services provider Quest Diagnostics. Under the terms of the non-exclusive deal, Seattle, Washington-based Quest will be able to incorporate the biomarker in a molecular-based, lab-developed test and commercialise the product. Financial details of the agreement were not disclosed. The test will detect DNA methylation of the gene GSTP1 in tissue samples. When combined with conventional histopathology, it can help doctors diagnose more accurately prostate cancer. This could benefit cases where the patients have suspicious or inconclusive histology results, or where they have elevated levels of prostate-specific antigens (PSA) in their blood, but have negative biopsies.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT042238

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel